Tuesday, 30 April 2013

Johnson & Johnson's licence for cosmetics cancelled

The Food and Drug Administration (FDA) recently cancelled Johnson & Johnson India’s license to produce cosmetic products at their Mulund plant. FDA’s order will come into effect from June 24.

According to FDA officials, the order was issued in a case dating back to 2007 when they found that 15 batches of Johnson & Johnson baby powder were sterilized by ethylene oxide, a known carcinogenic and irritant.

 “While Ethylene Oxide can be used for sterilisation, the company did not bother to carry out a test after the process to check the amount of residue in the product,” said FDA joint commissioner KB Shende, adding that the company can appeal to the state government before the order comes into effect.

  “The products are used for new born babies. IT IS MUST for the company to follow all measures,” said Shende adding that the traces of ethylene oxide, if any, should have been measured. The 15 batches in question consisted of 160,000 containers.

Monday, 29 April 2013

Clinical Research News

Promising Phase I Clinical Trial of Rogosertib Leads To Multi-Institutional Phase II Trial
Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This is the first trial in which orally administered Rigosertib, a dual kinase inhibitor, was studied in solid tumors. Intravenously rigosertib is already in phase 3 clinical trials for myelodysplastic syndrome and pancreatic cancer and oral rigosertib is being studied in a pair of Phase II trials in lower-risk transfusion dependent MDS patients. The drug candidate is being developed by Onconova Therapeutics, Inc., of Pennington, NJ. 

Tuesday, 16 April 2013

Three top students of November batch

          Three top students of November batch


          Dr Neethu,
          •MMSH,Medical Writing

        •Dr Savitha
        Synowledge, Drug safety associate 


      •Dr Nihar
           • Indegene,Clinical Trial Analyst

Friday, 12 April 2013

How does it feel when a most desirable position in the CR world- medical writing in this case, comes as a windfall, you may want to ask Ms Madhurya  on how they feels on being on cloud nine who got selected with MNC at an attractive pay package. - Congratulations Madhurya. Avigna Clinical Research Institute review

Sunday, 7 April 2013


  • Learnt about the current scenario of India Pharmaceutical Market.
  • Gained depth knowledge of Pharmacovigilence and its process.
  • Learnt about the current Guidelines applied for periodic safety update reports.
  • Learnt about the transfer of adverse event information from vigiflow to vigibase.
  • Ethics committee and its quality in India.

Pictures of Workshop

 Students and staff of ACRI @ Workshop

Students and Staff of ACRI attended a workshop on dia

4th Pharmacovigilence conference took place in Bangalore from 8th to 9th March 2013.  It was held in the Vivanta by Taj – Yeshwantpur Bangalore. 

Inauguration and opening remark was by:         

   Dr Moin Don  - Director and Founder of PVCON, PV Consulting Services.
   Dr Vivek Ahuja - Director, Pharmacovigilance Asia Pacific, Baxter Healthcare.                                             

Friday, 5 April 2013

Avigna Clinical Research Institute: Review

Joining an MNC is every young graduates dream and two of our candidates, Mr Venu Madhav got selected for a leading American Healthcare company with an attractive salary.